- Home
- PETS vs MREO Comparison
PETS vs MREO Comparison
Compare PETS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | MREO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 67.5M |
| IPO Year | 2003 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PETS | MREO |
|---|---|---|
| Price | $2.44 | $0.40 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.20 | ★ $3.90 |
| AVG Volume (30 Days) | 95.0K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | $6,363.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.20 |
| 52 Week High | $4.32 | $2.94 |
Technical Indicators
Market Signals| Indicator | PETS | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 27.80 | 42.00 |
| Support Level | $2.44 | $0.35 |
| Resistance Level | $2.93 | $0.45 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 20.20 | 70.30 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).